Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dendritic cell vaccine + cytokine-induced killer cells
- Development stage
- Phase 3
- Lead developer
- Clínica Universidad de Navarra
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
Dendritic cell vaccine + cytokine-induced killer cells (DC-CIK) is an immunotherapeutic approach that combines dendritic cells (DCs) and cytokine-induced killer (CIK) cells to enhance anti-tumor immune responses. DCs function as antigen-presenting cells that capture and process tumor antigens, while CIK cells are a unique population of cytotoxic T lymphocytes with the CD3+CD56+ phenotype. When used together, DCs activate CIK cells, significantly enhancing their anti-tumor activity. This therapy is typically administered alongside conventional treatments like chemotherapy to improve clinical outcomes in cancer patients.
- Other names
- DC-CIKDCV-CIKDC/CIK
Beyond the preview
Go deeper on dendritic cell vaccine + cytokine-induced killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dendritic cell vaccine + cytokine-induced killer cells.